For prescribing information, click here

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience. If you are not a Healthcare Professional, please click here.
Adverse event reporting information is available at the bottom of this webpage.

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience

All materials

OnCo on Air NETs – Episode 2 – How will my NET treatment be managed in Ireland?

Neuroendocrine Tumours (NETs) Video
20:27

In this podcast ‘How will my NET treatment be managed in Ireland?‘ episode, Dr Gregory Leonard and Mark McDonnell aim to help patients understand the treatment of NETs. They discuss some of the treatment options available for patients with NETs in Ireland and how a multidisciplinary team can help patients navigate their treatment journey.

SOM-IE-000756 | November 2025

Explore more Neuroendocrine Tumours (NETs) Resources

Explore more Neuroendocrine Tumours (NETs) Resources

Browse

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

To access relevant information about Neuroendocrine Tumours (NETs), please choose one of the following options:

I am a Healthcare Professional in Ireland

This section of the website is for healthcare professionals in Ireland only and contains promotional content regarding our medicines

I am a Healthcare Professional in Ireland

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

I am a patient

This section provides information to support patients that have been prescribed Somatuline® Autogel® (lanreotide). It has been designed for Irish patients and should not replace the details contained in the Patient Information Leaflet.

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.